Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 18, 2016 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Paul LaViolette |
Contact Details
Address: 601 Brickell Key Drive, Suite 1080 Miami, Florida 33131 United States | |
| Phone | 510-906-4600 |
| Website | pulsebiosciences.com |
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| Employer ID | 46-5696597 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Arthur LaViolette | President, Chief Executive Officer and Co-Chairman of the Board |
| Darrin R. Uecker | Chief Technology Officer and Director |
| Kevin P. Danahy | Chief Commercial Officer |
| Jon Skinner | Chief Financial Officer |
| Edison Manuel | Vice President of Operations |
| Steven T. Weber | Vice President of Accounting, Principal Accounting Officer and Global Corporate Controller |
| Kenneth B. Stratton Esq., J.D. | General Counsel and Corporate Secretary |
| Patty Perla | Vice President of Human Resources |
| Mitchell E. Levinson | Chief Strategy Officer |
| David Danitz | Senior Vice President of Engineering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 9, 2026 | 8-K | Current Report |
| Mar 3, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 8-K/A | [Amend] Current report |
| Feb 27, 2026 | EFFECT | Notice of Effectiveness |
| Feb 27, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 8-K | Current Report |
| Feb 19, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 19, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 19, 2026 | 424B5 | Filing |
| Feb 19, 2026 | 8-K | Current Report |